OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina

Core Insights - OXB has acquired a state-of-the-art viral vector manufacturing facility in North Carolina from RTP Operating, LLC, enhancing its capabilities in the cell and gene therapy sector [1][8] - The acquisition aligns with OXB's strategic initiatives to expand its US commercial capabilities and meet growing client demand [4][7] Group 1: Acquisition Details - The facility is FDA approved and adds commercial-scale GMP capacity, enabling OXB to support late-stage programs and commercial launches for clients worldwide, particularly in the adeno-associated virus (AAV) field [2][9] - OXB paid $4.5 million (£3.4 million) for the assets, funded by existing cash, with integration planning expected to be operational by Q1 2026 [5][6] Group 2: Operational Enhancements - The North Carolina site includes two operational GMP drug substance suites, a dedicated fill-finish suite, and on-site QC labs, complementing OXB's existing global network [3][11] - The company plans to invest in the new facility, including hiring additional operational staff to enhance US fill-finish capacity and expedite client onboarding [6][8] Group 3: Financial Outlook - The acquisition is expected to support OXB's long-term top-line growth and maintain existing financial guidance, with an anticipated single-digit gain in 2025 [5][7] - OXB aims to achieve EBITDA profitability from FY 2025 and strengthen its competitive position in the global viral vector market [7][9]